2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimizu-Hirota, R. Articles by Saruta, T. Search for Related Content PubMed PubMed Citation Articles by Shimizu-Hirota, R. Articles by Saruta, T.

Regulation of Vascular Proteoglycan Synthesis by Angiotensin II Type 1 and Type 2 Receptors

Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.

Correspondence to Dr. Hiroyuki Sasamura, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Phone: +81-3-3353-1211; Fax: +81-3-3359-2745; E-mail: sasamura{at}mc.med.keio.ac.jp

ABSTRACT. Recent studies have shown that proteoglycans play an important role in the development of vascular disease and renal failure. In this study, the effects of angiotensin II (AngII) type 1 (AT1) and type 2 (AT2) receptor stimulation on glycosaminoglycan and proteoglycan core protein synthesis in vascular smooth muscle cells (VSMC) were examined. Treatment of AT1 receptor-expressing VSMC with AngII resulted in a dose-dependent and time-dependent increase (2- to 4-fold) in ³H-glucosamine/³⁵S-sulfate incorporation, which was abolished by pretreatment with the AT1 receptor antagonist, losartan. The effects of AngII were inhibited by the epidermal growth factor receptor inhibitor, AG1478, and the mitagen-activated protein kinase kinase inhibitor, PD98059, but not the protein kinase C inhibitors, chelerythrine and staurosporine. AngII treatment also resulted in significant increases in the mRNA of the core proteins, versican, biglycan, and perlecan. The effects of AT2 receptor stimulation were examined by retroviral transfection of VSMC with the AT2 receptor. Stimulation of the AT2 receptor in these VSMC-AT2 cells resulted in a significant (1.3-fold) increase in proteoglycan synthesis, which was abolished by the AT2 receptor antagonist, PD123319, and attenuated by pretreatment with pertussis toxin. These results implicate both AT1 and AT2 receptors in the regulation of proteoglycan synthesis and suggest the involvement of epidermal growth factor receptor-dependent tyrosine kinase pathways and Gi/o-mediated mechanisms in the effects of the two receptors.

This article has been cited by other articles:

				F. Huang, J. C. Thompson, P. G. Wilson, H. H. Aung, J. C. Rutledge, and L. R. Tannock Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development J. Lipid Res., March 1, 2008; 49(3): 521 - 530. [Abstract] [Full Text] [PDF]

				K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res, October 1, 2007; 76(1): 19 - 28. [Abstract] [Full Text] [PDF]

				P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]

				M. Rahmani, J. T. Read, J. M. Carthy, P. C. McDonald, B. W. Wong, M. Esfandiarei, X. Si, Z. Luo, H. Luo, P. S. Rennie, et al. Regulation of the Versican Promoter by the {beta}-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells J. Biol. Chem., April 1, 2005; 280(13): 13019 - 13028. [Abstract] [Full Text] [PDF]

				T. N. Wight and M. J. Merrilees Proteoglycans in Atherosclerosis and Restenosis: Key Roles for Versican Circ. Res., May 14, 2004; 94(9): 1158 - 1167. [Abstract] [Full Text] [PDF]

				R. Shimizu-Hirota, H. Sasamura, M. Kuroda, E. Kobayashi, M. Hayashi, and T. Saruta Extracellular Matrix Glycoprotein Biglycan Enhances Vascular Smooth Muscle Cell Proliferation and Migration Circ. Res., April 30, 2004; 94(8): 1067 - 1074. [Abstract] [Full Text] [PDF]

				P.-T. Brinkkoetter, S. Holtgrefe, F. J. van der Woude, and B. A. Yard Angiotensin II Type 1-Receptor Mediated Changes in Heparan Sulfate Proteoglycans in Human SV40 Transformed Podocytes J. Am. Soc. Nephrol., January 1, 2004; 15(1): 33 - 40. [Abstract] [Full Text] [PDF]

				K. Tiede, K. Stoter, C. Petrik, W.-B. Chen, H. Ungefroren, M.-L. Kruse, M. Stoll, T. Unger, and J. W Fischer Angiotensin II AT1-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGF{beta} in vitro Cardiovasc Res, December 1, 2003; 60(3): 538 - 546. [Abstract] [Full Text] [PDF]

				M. S. Ahmed, E. Oie, L. E. Vinge, A. Yndestad, G. O. Andersen, Y. Andersson, T. Attramadal, and H. Attramadal Induction of myocardial biglycan in heart failure in rats--an extracellular matrix component targeted by AT1 receptor antagonism Cardiovasc Res, December 1, 2003; 60(3): 557 - 568. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673